Netrin-1 blockade inhibits tumour growth and EMT features in endometrial cancer
View abstract on PubMed
Summary
This summary is machine-generated.Netrin-1 blockade with antibody NP137 shows promise in endometrial cancer (EC). It reduced tumor progression in mice and patients, inhibited epithelial-to-mesenchymal transition (EMT), and improved chemotherapy response.
Area Of Science
- Oncology
- Cancer Biology
- Immunotherapy
Background
- Netrin-1 is upregulated in cancers, promoting tumor growth.
- Endometrial carcinoma (EC) shows high netrin-1 expression.
- Epithelial-to-mesenchymal transition (EMT) contributes to treatment resistance.
Purpose Of The Study
- To evaluate the efficacy of netrin-1 blockade using anti-netrin-1 antibody (NP137) in endometrial carcinoma.
- To investigate the mechanism of action of NP137, including its effect on EMT and the tumor microenvironment.
- To assess the combination therapy of NP137 with standard chemotherapy in an EC mouse model.
Main Methods
- Netrin-1 blockade using NP137 in an EC mouse model.
- Phase I clinical trial of NP137 in advanced EC patients.
- Tumor gene profiling, bulk RNA-seq, spatial transcriptomics, and single-cell RNA-seq on patient biopsies.
- Combination therapy of NP137 with carboplatin-paclitaxel in an EC mouse model.
Main Results
- NP137 demonstrated efficacy in reducing tumor progression in both mouse models and human EC patients (8/14 stable disease, 1 partial response).
- NP137 inhibited tumor epithelial-to-mesenchymal transition (EMT), induced cell death, and altered immune infiltrate.
- Combination therapy of NP137 with carboplatin-paclitaxel showed superior outcomes compared to chemotherapy alone in the EC mouse model.
Conclusions
- Netrin-1 blockade with NP137 is a promising clinical strategy for endometrial carcinoma.
- NP137 exhibits anti-tumor effects by inducing debulking and inhibiting EMT, potentially overcoming treatment resistance.
- This approach may enhance the efficacy of standard chemotherapies in advanced EC.
Related Concept Videos
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
The cadherins are a superfamily of cell adhesion molecules comprising over 180 variants, with specific tissues expressing a particular combination of cadherin types. Cadherins generally exhibit homophilic binding; i.e., cadherins on one cell bind to cadherins of the same or closely related type on another cell. Thus, cells of the same type have a specific affinity to bind to each other and sort themselves into clusters to form tissues.
Cell Sorting During Development
Cell sorting plays an...

